Revisiting the mouse model of oxygen-induced retinopathy

Eye and Brain

Volumn 8, Issue , 2016, Pages 67-79

  Kim, Clifford B ^a   D'Amore, Patricia A ^b   Connor, Kip M ^c  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; OIR; ROP

Indexed keywords

ANGIOGENIC FACTOR; OXYGEN;

CLINICAL OBSERVATION; HYPEROXIA; LACTATION; LIGHT EXPOSURE; MOTHER; MOUSE MODEL; NONHUMAN; OXYGEN-INDUCED RETINOPATHY; PHENOTYPE; RETINA DEVELOPMENT; REVIEW; WEIGHT GAIN;

EID: 84978374578     PISSN: 11792744     EISSN: None     Source Type: Journal    
DOI: 10.2147/EB.S94447     Document Type: Review

References (118)

1. Terry TL. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely: II. Report of cases-clinical aspects. Trans Am Ophthalmol Soc. 1942;40:262-284.
2. Terry TL. Retrolental fibroplasia in the premature infant: V. Further studies on fibroplastic overgrowth of the persistent tunica vasculosa lentis. Trans Am Ophthalmol Soc. 1944;42:383-396.
3. Wilson JL, Long SB, Howard PJ. Respiration of premature infants. Am J Dis Child. 1942;63(6):1080.
4. Tin W, Gupta S. Optimum oxygen therapy in preterm babies. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F143-F147.
5. Bedrossian RH, Carmichael P, Ritter J. Retinopathy of prematurity (retrolental fibroplasia) and oxygen. Am J Ophthalmol. 1954;37(1):78-86.
6. Zacharias L, Reynolds WE, Chisholm JF, King MJ. The incidence and severity of retrolental fibroplasia in relation to possible causative factors. I. Observations on the occurrence of retrolental fibroplasia. II. Studies of the relationship of retrolental fibroplasia to degree of prematurity, oxygen therapy, general health, and date of birth of premature infants. Am J Ophthalmol. 1954;38(3):317-336.
7. Parmelee AH, Pilger IS, Austin WO. Retrolental fibroplasia; a reduction in incidence following a decrease in use of oxygen therapy for premature infants. Calif Med. 1956;84(6):424-426.
8. Szewczyk TS. Retrolental fibroplasia; etiology and prophylaxis. Am J Ophthalmol. 1952;35(3):301-311.
9. Szewczyk TS. Retrolental fibroplasia and related ocular diseases; classifica tion, etiology, and prophylaxis. Am J Ophthalmol. 1953;36(10): 1336-1361.
10. Ashton N, Ward B, Serpell G. Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol. 1954;38(7):397-432.
11. Gerschman R, Nadig PW, Snell AC, Nye SW. Effect of high oxygen concentrations on eyes of newborn mice. Am J Physiol. 1954;179(1): 115-118.
12. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Vis Sci. 1948;68:137-180.
13. Ashton N, Ward B, Serpell G. Role of oxygen in the genesis of retrolental fibroplasia. Br J Ophthalmol. 1953;37(9):513-520.
14. Gyllensten LJ, Hellström BE. Experimental approach to the pathogenesis of retrolental fibroplasia. Br J Ophthalmol. 1955;39(7):409-415.
15. Gyllensten LJ, Hellström BE. Retrolental fibroplasia; animal experiments: the effect of intermittently administered oxygen on the postnatal development of the eyes of full term mice. Acta Paediatr. 1952;41(6):577-582.
16. Patz A, Eastham A, Higginbotham DH, Kleh T. Oxygen studies in retrolental fibroplasia. Am J Ophthalmol. 1953;36(11):1511-1522.
17. Habegger H, Randolf Philbrook F, Curley FJ, Ingalls TH. Retinopathy of immaturity. Am J Ophthalmol. 1956;42(3):377-392.
18. Gyllensten LJ, Hellström BE. Experimental approach to the pathogenesis of retrolental fibroplasia. I. Changes of the eye induced by exposure of newborn mice to concentrated oxygen. Acta Paediatr Suppl. 1954;43(100):131-148.
19. Smith LEH, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):101-111.
20. Gole GA, Browning J, Elts SM. The mouse model of oxygen-induced retinopathy: a suitable animal model for angiogenesis research. Doc Ophthalmol. 1990;74(3):163-169.
21. Patz A. I. Studies on retinal NV. Invest Ophthalmol Vis Sci. 1980;10(10): 1133-1138.
22. Bischoff PM, Wajer SD, Flower RW. Scanning electron microscopic studies of the hyaloid vascular system in newborn mice exposed to O2 and CO2 . Graefe's Arch Clin Exp Ophthalmol. 1983;220(6): 257-263.
23. Novotny HR, Alvis DL. A method of photographing fluorescence in circulating blood in the human retina. Circulation. 1961;24:82-86.
24. Keane PA, Sadda SR. Retinal imaging in the twenty-first century. Ophthalmology. 2014;121(12):2489-2500.
25. Blanks JC, Johnson LV. Selective lectin binding of the developing mouse retina. J Comp Neurol. 1983;221(1):31-41.
26. Connolly SE, Hores TA, Smith LEH, D'Amore PA. Characterization of vascular development in the mouse retina. Microvasc Res. 1988;36(3):275-290.
27. D'Amato R, Wesolowski E, Smith LE. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res. 1993;46(2):135-142.
28. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275-288.
29. Glaser BM, D'Amore PA, Michels RG, et al. The demonstration of angiogenic activity from ocular tissues. Preliminary report. Ophthalmology. 1980;87(5):440-446.
30. Glaser BM, D'Amore PA, Michels RG, Patz A, Fenselau A. Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol. 1980;84(2):298-304.
31. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787): 442-447.
32. Ashton N. Some aspects of the comparative pathology of oxygen toxicity in the retina. Ophthalmologica. 1970;160(1):54-71.
33. Phelps DL, Rosenbaum AL. Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model. Pediatrics. 1984;73(1):1-6.
34. Connor KM, Krah NM, Dennison RJ, et al. Quantification of oxygeninduced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4(11):1565-1573.
35. Stahl A, Connor KM, Sapieha P, et al. Computer-aided quantification of retinal NV. Angiogenesis. 2009;12(3):297-301.
36. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51(6):2813-2826.
37. Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122(1):200-210.
38. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003;8(12):1030-1043.
39. Dorrell MI, Friedlander M. Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. Prog Retin Eye Res. 2006;25(3):277-295.
40. Aguilar E, Dorrell MI, Friedlander D, et al. Chapter 6. Ocular models of angiogenesis. Methods Enzymol. 2008;444:115-158.
41. Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 2000;118(5):645-649.
42. Lange C, Ehlken C, Stahl A, Martin G, Hansen L, Agostini HT. Kinetics of retinal vaso-obliteration and NV in the oxygen-induced retinopathy (OIR) mouse model. Graefe's Arch Clin Exp Ophthalmol. 2009;247(9):1205-1211.
43. Gu X, Samuel S, El-Shabrawey M, et al. Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2002;43(2):496-502.
44. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci. 1999;40(1):182-189.
45. Scott A, Fruttiger M. Oxygen-induced retinopathy: a model for vascular pathology in the retina. Eye (Lond). 2010;24(3):416-421.
46. Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V, Dvorak H. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-985.
47. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851-858.
48. D'Amore PA. Mechanisms of retinal and choroidal NV. Invest Ophthalmol Vis Sci. 1994;35(12):3974-3979.
49. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574-584.
50. Shima DT, Gougos A, Miller JW, et al. Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci. 1996;37(7):1334-1340.
51. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal NV. Proc Natl Acad Sci U S A. 1995;92(3): 905-909.
52. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15(7 Pt 1):4738-4747.
53. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal NV in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92(23):10457-10461.
54. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024-1028.
55. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114(10):1219-1228.
56. Sweigard JH, Yanai R, Gaissert P, et al. The alternative complement pathway regulates pathological angiogenesis in the retina. FASEB J. 2014;28(7):3171-3182.
57. Stalmans I, Ng YS, Rohan R, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest. 2002;109(3):327-336.
58. Ferrari G, Cook BD, Terushkin V, Pintucci G, Mignatti P. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol. 2009;219(2):449-458.
59. Chen J, Connor KM, Aderman CM, Smith LEH. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118(2):526-533.
60. Lofqvist C, Willett KL, Aspegren O, et al. Quantification and localization of the IGF/insulin system expression in retinal blood vessels and neurons during oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2009;50(4):1831-1837.
61. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007;13(7):868-873.
62. Van Wijngaarden P, Coster DJ, Brereton HM, Gibbins IL, Williams KA. Strain-dependent differences in oxygen-induced retinopathy in the inbred rat. Invest Ophthalmol Vis Sci. 2005;46(4):1445-1452.
63. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000;14(7):871-876.
64. Chan CK, Pham LN, Chinn C, et al. Mouse strain-dependent heterogeneity of resting limbal vasculature. Invest Ophthalmol Vis Sci. 2004;45(2):441-447.
65. Walsh N, Bravo-Nuevo A, Geller S, Stone J. Resistance of photoreceptors in the C57BL/6-c2J, C57BL/6J, and BALB/cJ mouse strains to oxygen stress: evidence of an oxygen phenotype. Curr Eye Res. 2004;29(6):441-447.
66. Chan CK, Pham LN, Zhou J, Spee C, Ryan SJ, Hinton DR. Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal NV. Lab Invest. 2005;85(6):721-733.
67. Vanhaesebrouck S, Daniels H, Moons L, Vanhole C, Carmeliet P, De Zegher F. Oxygen-induced retinopathy in mice: amplification by neonatal IGF-I deficit and attenuation by IGF-I administration. Pediatr Res. 2009;65(3):307-310.
68. Tan SM, Stefanovic N, Tan G, Wilkinson-Berka JL, de Haan JB. Lack of the antioxidant glutathione peroxidase-1 (GPx1) exacerbates retinopathy of prematurity in mice. Invest Ophthalmol Vis Sci. 2013;54(1):555-562.
69. Sears JE, Pietz J, Sonnie C, Dolcini D, Hoppe G. A change in oxygen supplementation can decrease the incidence of retinopathy of prematurity. Ophthalmology. 2009;116(3):513-518.
70. Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177(6):2715-2723.
71. Bergman PB, Moravski CJ, Edmondson SR, et al. Expression of the IGF system in normal and diabetic transgenic (mRen-2)27 rat eye. Invest Ophthalmol Vis Sci. 2005;46(8):2708-2715.
72. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr Med Chem. 2006;13(27):3307-3317.
73. Hellström A, Hård A-L, Engström E, et al. Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics. 2009;123(4):e638-e645.
74. Löfqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006;124(12):1711-1718.
75. Löfqvist C, Hansen-Pupp I, Andersson E, et al. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009;127(5):622-627.
76. Holmes JM, Duffner LA. The effect of postnatal growth retardation on abnormal NV in the oxygen exposed neonatal rat. Curr Eye Res. 1996;15(4):403-409.
77. Ackerman B, Sherwonit E, Williams J. Reduced incidental light exposure: effect on the development of retinopathy of prematurity in low birth weight infants. Pediatrics. 1989;83(6):958-962.
78. Glass P, Avery GB, Subramanian KN, Keys MP, Sostek AM, Friendly DS. Effect of bright light in the hospital nursery on the incidence of retinopathy of prematurity. N Engl J Med. 1985;313(7):401-404.
79. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35(1):112-119.
80. Ricci B, Lepore D, Iossa M, Santo A, D'urso M, Maggiano N. Effect of light on oxygen-induced retinopathy in the rat model. Doc Ophthalmol. 1990;74(4):287-301.
81. Kremer I, Levitt A, Goldberg G, Wilunsky E, Merlob P, Nissenkorn I. The effect of light on oxygen-induced vasoproliferative retinopathy in newborn kittens. Invest Ophthalmol Vis Sci. 1992;33(5):1595-1598.
82. Dorfman AL, Joly S, Hardy P, Chemtob S, Lachapelle P. The effect of oxygen and light on the structure and function of the neonatal rat retina. Doc Ophthalmol. 2008;118(1):37-54.
83. Natoli R, Valter K, Barbosa M, et al. 670nm photobiomodulation as a novel protection against retinopathy of prematurity: evidence from oxygen induced retinopathy models. PLoS One. 2013;8(8):e72135.
84. Emberson JR, Whincup PH, Walker M, Thomas M, Alberti KGMM. Biochemical measures in a population-based study: effect of fasting duration and time of day. Ann Clin Biochem. 2002;39(Pt 5):493-501.
85. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal NV by insulin-like growth factor-1 receptor. Nat Med. 1999;5(12):1390-1395.
86. Higgins RD, Yu K, Sanders RJ, Nandgaonkar BN, Rotschild T, Rifkin DB. Diltiazem reduces retinal NV in a mouse model of oxygen induced retinopathy. Curr Eye Res. 1999;18(1):20-27.
87. Lange C, Ehlken C, Martin G, et al. Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal NV in mice. Exp Eye Res. 2007;85(3):323-327.
88. Ritter MR, Banin E, Moreno SK, Aguilar E, Dorrell MI, Friedlander M. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J Clin Invest. 2006;116(12):3266-3276.
89. Banin E, Dorrell MI, Aguilar E, et al. T2-TrpRS inhibits preretinal NV and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006;47(5):2125-2134.
90. Penn JS, Gay CA. Computerized digital image analysis of retinal vessel density: application to normoxic and hyperoxic rearing of the newborn rat. Exp Eye Res. 1992;54(3):329-336.
91. Davies MH, Stempel AJ, Powers MR. MCP-1 deficiency delays regression of pathologic retinal NV in a model of ischemic retinopathy. Invest Ophthalmol Vis Sci. 2008;49(9):4195-4202.
92. Paques M, Guyomard JL, Simonutti M, et al. Panretinal, high-resolution color photography of the mouse fundus. Invest Ophthalmol Vis Sci. 2007;48(6):2769-2774.
93. Furtado JM, Davies MH, Choi D, et al. Imaging retinal vascular changes in the mouse model of oxygen-induced retinopathy. Transl Vis Sci Technol. 2012;1(2):5.
94. Mezu-Ndubuisi OJ, Teng P, Wanek J, et al. In vivo retinal vascular oxygen tension imaging and fluorescein angiography in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2013;54(10):6968-6972.
95. Ishikawa K, Yoshida S, Kadota K, et al. Gene expression profile of hyperoxic and hypoxic retinas in a mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2010;51(8):4307.
96. Zhu Y, Natoli R, Valter K, Stone J. Differential gene expression in mouse retina related to regional differences in vulnerability to hyperoxia. Mol Vis. 2010;16:740-755.
97. Miyamoto N, Mandai M, Takagi H, et al. Contrasting effect of estrogen on VEGF induction under different oxygen status and its role in murine ROP. Invest Ophthalmol Vis Sci. 2002;43(6):2007-2014.
98. Brothwood M, Wolke D, Gamsu H, Benson J, Cooper D. Prognosis of the very low birthweight baby in relation to gender. Arch Dis Child. 1986;61(6):559-564.
99. Phelps DL, Brown DR, Tung B, et al. 28-day survival rates of 6676 neonates with birth weights of 1250 grams or less. Pediatrics. 1991;87(1):7-17.
100. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991;98(11):1628-1640.
101. Yang MB, Donovan EF, Wagge JR. Race, gender, and clinical risk index for babies (CRIB) score as predictors of severe retinopathy of prematurity. J AAPOS. 2006;10(3):253-261.
102. Flower RW, McLeod DS, Lutty GA, Goldberg B, Wajer SD. Postnatal retinal vascular development of the puppy. Invest Ophthalmol Vis Sci. 1985;26(7):957-968.
103. Shabo AL, Maxwell DS. Insulin-induced immunogenic retinopathy resembling the retinitis proliferans of diabetes. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1976;81(3 Pt 1):497-508.
104. Langer HF, Chung K-J, Orlova VV, et al. Complement-mediated inhibition of NV reveals a point of convergence between innate immunity and angiogenesis. Blood. 2010;116(22):4395-4403.
105. Ishida S, Yamashiro K, Usui T, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9(6):781-788.
106. Vessey KA, Wilkinson-Berka JL, Fletcher EL. Characterization of retinal function and glial cell response in a mouse model of oxygeninduced retinopathy. J Comp Neurol. 2011;519(3):506-527.
107. Dorrell MI, Aguilar E, Jacobson R, et al. Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia. 2010;58(1):43-54.
108. Liu X, Wang D, Liu Y, et al. Neuronal-driven angiogenesis: role of NGF in retinal NV in an oxygen-induced retinopathy model. Invest Ophthalmol Vis Sci. 2010;51(7):3749-3757.
109. Saito Y, Geisen P, Uppal A, Hartnett ME. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis. 2007;13:840-853.
110. Wilkinson-Berka JL, Deliyanti D, Rana I, et al. NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. Antioxid Redox Signal. 2014;20(17):2726-2740.
111. Wang H, Zhang SX, Hartnett ME. Signaling pathways triggered by oxidative stress that mediate features of severe retinopathy of prematurity. JAMA Ophthalmol. 2013;131(1):80-85.
112. Li S-Y, Fu ZJ, Lo ACY. Hypoxia-induced oxidative stress in ischemic retinopathy. Oxid Med Cell Longev. 2012;2012:426769.
113. Tan SM, Deliyanti D, Figgett WA, Talia DM, de Haan JB, Wilkinson-Berka JL. Ebselen by modulating oxidative stress improves hypoxiainduced macroglial Müller cell and vascular injury in the retina. Exp Eye Res. 2015;136:1-8.
114. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52(1):155-170.
115. Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119(6):1317-1329.
116. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal NV. Prog Retin Eye Res. 2010;29(6):500-519.
117. Cao Z, Jensen LD, Rouhi P, et al. Hypoxia-induced retinopathy model in adult zebrafish. Nat Protoc. 2010;5(12):1903-1910.
118. Cao R, Jensen LDE, Söll I, Hauptmann G, Cao Y. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One. 2008;3(7):e2748.